Metabolomic and Lipidomic Signatures of Metabolic Syndrome and its Physiological Components in Adults: A Systematic Review.
Stéphanie MonnerieBlandine ComteDaniela ZieglerJosé A MoraisEstelle Pujos-GuillotPierrette GaudreauPublished in: Scientific reports (2020)
The aim of this work was to conduct a systematic review of human studies on metabolite/lipid biomarkers of metabolic syndrome (MetS) and its components, and provide recommendations for future studies. The search was performed in MEDLINE, EMBASE, EMB Review, CINHAL Complete, PubMed, and on grey literature, for population studies identifying MetS biomarkers from metabolomics/lipidomics. Extracted data included population, design, number of subjects, sex/gender, clinical characteristics and main outcome. Data were collected regarding biological samples, analytical methods, and statistics. Metabolites were compiled by biochemical families including listings of their significant modulations. Finally, results from the different studies were compared. The search yielded 31 eligible studies (2005-2019). A first category of articles identified prevalent and incident MetS biomarkers using mainly targeted metabolomics. Even though the population characteristics were quite homogeneous, results were difficult to compare in terms of modulated metabolites because of the lack of methodological standardization. A second category, focusing on MetS components, allowed comparing more than 300 metabolites, mainly associated with the glycemic component. Finally, this review included also publications studying type 2 diabetes as a whole set of metabolic risks, raising the interest of reporting metabolomics/lipidomics signatures to reflect the metabolic phenotypic spectrum in systems approaches.
Keyphrases
- metabolic syndrome
- type diabetes
- case control
- mass spectrometry
- ms ms
- cardiovascular disease
- systematic review
- endothelial cells
- genome wide
- gene expression
- mental health
- big data
- multiple sclerosis
- dna methylation
- risk assessment
- machine learning
- drug delivery
- current status
- fatty acid
- human health
- adverse drug
- weight loss